Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Non-Current Liabilities (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $208.8 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 121.28% to $208.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $208.8 million through Dec 2025, up 121.28% year-over-year, with the annual reading at $208.8 million for FY2025, 121.28% up from the prior year.
  • Total Non-Current Liabilities hit $208.8 million in Q4 2025 for ARS Pharmaceuticals, down from $221.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $221.4 million in Q3 2025 to a low of $8.5 million in Q4 2022.
  • Historically, Total Non-Current Liabilities has averaged $111.6 million across 4 years, with a median of $107.0 million in 2024.
  • Biggest five-year swings in Total Non-Current Liabilities: plummeted 48.48% in 2022 and later skyrocketed 121.28% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $16.6 million in 2021, then tumbled by 48.48% to $8.5 million in 2022, then skyrocketed by 1003.7% to $94.4 million in 2024, then skyrocketed by 121.28% to $208.8 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for SPRY at $208.8 million in Q4 2025, $221.4 million in Q3 2025, and $119.7 million in Q2 2025.